by 
The recombinant human epidermal growth factor (EGF) is primarily used as an active ingredient in wound healing and tissue repairing therapies. EGF plays an important role in regulating cell proliferation, cell differentiation, tissue regeneration, angiogenesis and wound repair activities. Topical administration of recombinant EGF has been found to improve the healing process of various wounds and burns by enhancing migration, proliferation and protein synthesis in epithelial cells. In addition, recombinant EGF has also shown therapeutic potential in accelerating healing in diabetic ulcers, surgical wounds, burns and periodontal regeneration. In cancer research, EGF is used for in vitro cell culture experiments and plays a key role in cancer treatment drugs targeting EGF pathways.
The global recombinant human EGF market is estimated to be valued at US$ 10,251.1 Mn in 2023 and is expected to exhibit a CAGR of 9.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The increasing applications of recombinant human EGF protein in wound healing therapies and cancer treatment drives the market growth. EGF plays an important role in cell growth and regeneration and its topical administration helps in healing of various wounds and burns through enhanced cell migration, proliferation and protein synthesis. Furthermore, recombinant EGF is widely used in cell culture experiments for cancer research and development of EGF blocking drugs for cancer treatment which further boosts the market. However, high costs associated with recombinant protein production and stringent regulatory guidelines for clinical trials hamper the market growth. Companies are focusing on strategic collaborations to develop cost-effective production technologies to manufacture recombinant human EGF at large commercial scales and overcome these challenges.
Segment Analysis
The recombinant human (EGF) market is dominating by the biopharmaceutical segment which holds around 60% market share. The biopharmaceutical segment dominated the market as recombinant EGF proteins find wide usage in cell culture media for promoting cell proliferation, migration, and growth. They are also used in biotechnology research applications involving cell signaling, angiogenesis, and wound healing.
PEST Analysis
Political: The regulations regarding the usage of recombinant proteins are well established by bodies like FDA and EMA which ensures quality and safety. However, variations in regulations across countries can impact market dynamics.
Economic: The global economy recovering post-pandemic has increased research funding and demand from pharmaceutical and biotechnology industries which are driving market growth. However, inflation and economic uncertainties remain a challenge.
Social: With an aging population and increasing incidence of chronic diseases, the demand for effective therapeutics is increasing. Recombinant proteins play a significant role in developing innovative treatment options contributing to better health outcomes.
Technological: Advancements in gene expression systems, cell culture technologies, and purification methods have enhanced large-scale production capabilities and quality of recombinant proteins boosting their commercialization.
Key Takeaways
The global recombinant human (EGF) market is expected to witness high growth over the forecast period supported by increasing incidence of chronic wounds and cancers.
Regionally, North America dominated the market and held around 45% market share in 2024 owing to well-established healthcare infrastructure, robust research funding, and presence of key market players in the region. Europe was the second largest regional market.
Key players operating in the recombinant human (EGF) market are Thermo Fisher Scientific, FUJIFILM Irvine Scientific, Inc., ScienCell Research Laboratories, R&D Systems, Abcam PLC, Cell Sciences, Inc., Eurofins DiscoverX, PeproTech, Inc., RayBiotech, Inc., Prospec-Tany TechnoGene Ltd., Miltenyi Biotec, Tonbo Biosciences, BioLegend, Inc., EnQuire BioReagents, STEMCELL Technologies Inc., Cell Guidance Systems Ltd., Creative BioMart, Sino Biological Inc., and BioVision, Inc. These players are focusing on new product launches, acquisitions, and expansion strategies to strengthen their market presence. For instance, in 2022 Abcam PLC acquired BioVision, Inc. to expand its portfolio of life science research tools and assays.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.
